Navigation Links
Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
Date:7/10/2013

n July 2013, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Array Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Array's potential to earn future milestone and royalty payments under the agreement with Loxo, the potential for the results of preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, and future plans to progress and develop the programs licensed to Loxo, including the timing of clinical trials. These statements involve significant risks and uncertainties, including those discussed in Array's most recent annual report filed on form 10-K, in Array's quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect Array's current expectations concerning future events, actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, the ability of Loxo and of Array to meet objectives tied to milestones and royalties; risks associated with Array's dependence on Loxo and other collaborators for the clinical development a
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
2. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
3. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
4. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
8. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. ViewRays Chief Medical Officer Honored by American Society for Radiation Oncology (ASTRO)
10. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- This report analyzes the worldwide markets for Apheresis ... for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global ... Plateletpheresis, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Annual estimates and forecasts are provided for the period ...
(Date:4/21/2015)... -- Cardiologists at Henry Ford Hospital have implanted a device ... irregular heartbeat. With only handful of hospitals in ... able to add another option to its arsenal of tools ... ability to pump. "This is a first ... implant at a non-clinical trial site," says cardiologist Claudio ...
(Date:4/21/2015)... ALTO, Calif. , April 21, 2015 /PRNewswire/ ... endlessly, with the latest being the European Commission,s ... As a global leader and champion of ... the complexity of meeting these mandates and offers ... operate across many countries. From an upcoming webinar ...
Breaking Medicine Technology:World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Frequentz Gives the Global Pharmaceutical Supply Chain a Shoulder to Lean On as They Face Expanding Serialization Requirements 2Frequentz Gives the Global Pharmaceutical Supply Chain a Shoulder to Lean On as They Face Expanding Serialization Requirements 3
... IRIDEX Corporation (Nasdaq: IRIX ) (the "Company") ... Chief Executive Officer effective today. Dr. Beck replaces Theodore A. ... Officer, and will also replace Mr. Boutacoff on the IRIDEX ... the majority of his career in leadership and management roles ...
... DENVER, Oct. 10, 2011 MusclePharm Corporation, a Nevada ... U.S. nutritional supplement company, is pleased to announce MusclePharm,s ... 30, 2011. On a preliminary basis, the ... ended September 30, 2011 of approximately $5,700,000, an increase ...
Cached Medicine Technology:IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 2IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 3IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 4MusclePharm Announces Preliminary Third Quarter 2011 Results 2MusclePharm Announces Preliminary Third Quarter 2011 Results 3
(Date:4/21/2015)... 2015 Angelo’s FabriClean has recently announced ... for clients that avail the area rug cleaning services. ... done with hi-tech equipments, making use of the quick ... all natural, high pressure steam extraction to clean even ... for area rugs made with delicate fabric. , ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Catalent ... delivery technologies and development solutions for drugs, biologics ... of ADVASEPT™ Lock, a stopper-less, glass- and needle-free ... injectable medications. Easily opened, ADVASEPT Lock attaches to ... functional container closure with the security of an ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 QuickMedical, ... equipment and supplies, now represents Schiller America's ... Monitors, ECGs, Stress Tests, and Vital Signs Monitors, ... in Switzerland, is a global leader in the ... products are developed in close cooperation with the ...
(Date:4/21/2015)... The 2015 Market Research Report ... professional and in-depth study on the current state ... with a focus on the Chinese situation. ... market research are Cargill, Fbc Industries, Posy Pharmachem, ... Capchem, Lianyungang Mupro Fi, Yixing-Union, Debang Fine Chemical, ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Further strengthening ... committed $1.2 million in donated goods and services to ... care through the USF Health BRIDGE Healthcare Clinic. , ... community clinic in its eighth year – provides primary ... year one night a week inside the USF Health ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... VIEJO, Calif., Feb. 25 The Ensign,Group, ... company of the Ensign(TM) group of,skilled nursing, ... that GE Healthcare Financial Services has expanded,Ensign,s ... it an,additional five years., (Logo: ...
... WASHINGTON, Feb. 25 House Republican Whip,Roy Blunt ... legislation that will be introduced by Republican Leader ... in an effort to put,Medicare on a path ... sorely needed reforms to put,Medicare on a path ...
... for Medicare Advantage,Plans Sold to Senior Citizens, ... today that it will require UnitedHealth Group Inc.,(United) ... assets relating,to United,s Medicare Advantage business in the ... acquisition of Sierra. The Department said that the,transaction, ...
... L. Mitchell, M.D., M.P.H., of Hebrew SeniorLifes Institute ... with advanced dementia are frequently prescribed antibiotic medications, ... practice raises concerns about the end-of-life care of ... as the emergence of antimicrobial resistance. The paper ...
... place burden on Medicare, analysis finds , , MONDAY, Feb. ... Americans newly diagnosed with heart failure has declined, the ... new research finds. , The Duke University study analyzed ... diagnosed with heart failure between 1994 and 2003. It ...
... to increase the risk that women will have abnormal ... effectiveness of both methods for detecting breast cancer, according ... Archives of Internal Medicine, one of the JAMA/Archives journals. ... at the Los Angeles Biomedical Research Institute at Harbor-UCLA ...
Cached Medicine News:Health News:The Ensign Group Establishes $50 Million Credit Facility with GE Healthcare Financial Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 3Health News:Hebrew SeniorLife researcher finds 2Health News:Hebrew SeniorLife researcher finds 3Health News:More Elderly Americans Living With Heart Failure 2Health News:LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies 2
The standard of proximal press-fit design. The CLS hip is a straight stem design that is available in 13 sizes in two different neck angles, 135 and 145, to accommodate a wide variety of patient anat...
The Perfecta IMC Stems, manufactured from forged cobalt- chrome, are specifically designed for cemented femoral stem arthroplasty....
Classic proven design with superior clinical results....
The Link SP II Hip stem for cemented revisions...
Medicine Products: